Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

TASE:AZRG
TASE:AZRGReal Estate

Azrieli Group (TASE:AZRG) Valuation After Another Quarter of Sales and Profit Growth

Azrieli Group (TASE:AZRG) just posted another quarter of growth, with third quarter and nine month sales and profits climbing versus last year. Investors now need to judge how durable this trend looks. See our latest analysis for Azrieli Group. Even with those stronger earnings, the recent 30 day share price return of minus 7.29 percent and softer 7 day move suggest momentum has cooled a bit, though the 5 year total shareholder return of 77.77 percent still points to a rewarding long term...
NasdaqGS:MRVL
NasdaqGS:MRVLSemiconductor

Marvell (MRVL) EPS Surge Reinforces Bullish AI Profitability Narrative Despite Valuation Questions

Marvell Technology (MRVL) has turned in a punchy Q3 2026 print, with revenue of about $2.1 billion and basic EPS of $2.22, while net income (excluding extra items) came in at $1.9 billion as the latest marker of its profitability turnaround. The company has seen revenue move from $1.52 billion in Q3 2025 to $2.07 billion in Q3 2026 alongside a swing in net income from a loss of $676.3 million to a $1.9 billion profit, setting up a quarter where margins look materially healthier and far more...
NasdaqGM:JANX
NasdaqGM:JANXBiotechs

Janux Therapeutics (JANX) Is Down 50.7% After Positive JANX007 Phase 1 mCRPC Update - What's Changed

Janux Therapeutics recently reported positive updated interim Phase 1 data for its PSMA-directed TRACTr candidate JANX007 in metastatic castration-resistant prostate cancer, based on 109 treated patients as of the October 15, 2025 cutoff, and held a virtual event on December 1 to discuss the results. The update highlights not only progress for JANX007 but also reinforces Janux’s broader TRACTr and ARM platforms, which span multiple solid tumors and an emerging CD19 program in autoimmune...
NYSE:ASAN
NYSE:ASANSoftware

Asana (ASAN) Q3 2026: Wider Net Loss Challenges Gradual Path-to-Profitability Narrative

Asana (ASAN) just posted its Q3 2026 numbers, with revenue at about $201 million and basic EPS at roughly -$0.29. This keeps the focus firmly on how quickly the business can convert top line scale into a path toward profitability. The company has seen revenue move from around $179 million in Q2 2025 to roughly $201 million in Q3 2026, while basic EPS over that span has hovered between about -$0.31 and -$0.17. That sets up this quarter as another check in on whether margins are starting to...